QRG Capital Management Inc. Makes New $275,000 Investment in BioNTech SE (NASDAQ:BNTX)

QRG Capital Management Inc. acquired a new position in BioNTech SE (NASDAQ:BNTX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 2,415 shares of the company's stock, valued at approximately $275,000.

A number of other institutional investors have also recently bought and sold shares of the business. GSA Capital Partners LLP acquired a new stake in shares of BioNTech during the third quarter worth approximately $373,000. Baillie Gifford & Co. grew its holdings in shares of BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock valued at $986,750,000 after acquiring an additional 31,773 shares in the last quarter. Victory Capital Management Inc. acquired a new position in shares of BioNTech in the third quarter worth $345,000. Planning Capital Management Corp boosted its position in BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after purchasing an additional 450 shares during the last quarter. Finally, OneDigital Investment Advisors LLC purchased a new position in BioNTech in the third quarter valued at about $361,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $150.00 price target on shares of BioNTech in a research note on Monday, November 18th. Wells Fargo & Company assumed coverage on shares of BioNTech in a research report on Wednesday, December 11th. They set an "overweight" rating and a $170.00 price objective on the stock. Truist Financial began coverage on shares of BioNTech in a research report on Friday, January 10th. They issued a "buy" rating and a $172.00 target price for the company. Canaccord Genuity Group raised their price target on shares of BioNTech from $171.00 to $171.44 and gave the company a "buy" rating in a report on Wednesday, November 27th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a report on Tuesday, November 26th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, BioNTech presently has an average rating of "Moderate Buy" and an average target price of $142.72.

Remove Ads

BioNTech Stock Performance

NASDAQ BNTX traded down $3.43 during midday trading on Monday, hitting $105.35. The company had a trading volume of 1,170,882 shares, compared to its average volume of 789,512. The firm has a fifty day simple moving average of $116.91 and a two-hundred day simple moving average of $112.93. The stock has a market cap of $25.26 billion, a price-to-earnings ratio of -50.17 and a beta of 0.30. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech's quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.90 earnings per share. Equities analysts forecast that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.